How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

被引：9
|
作者：
Kunitoh, H.
Suzuki, K.
机构：
[1] Natl Canc Ctr, Dept Internal Med & Thorac Oncol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Thorac Surg, Chuo Ku, Tokyo 1040045, Japan
来源：
BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 10期
关键词：
trimodality; preoperative chemoradiotherapy; stage IIINSCLC; superior sulcus tumour;
D O I：
10.1038/sj.bjc.6603751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.
引用
收藏
页码：1498 / 1503
页数：6
相关论文
共 50 条
  • [1] How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
    H Kunitoh
    K Suzuki
    [J]. British Journal of Cancer, 2007, 96 : 1498 - 1503
  • [2] Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer: A Curative Approach
    Stupp, Roger
    Betticher, Daniel
    Ris, Hans-Beat
    Peters, Solange
    Pless, Miklos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : E118 - E119
  • [3] Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer: A Curative Approach Reply
    Friedel, Godehard
    Walles, Thorsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : E120 - E120
  • [4] Trimodality therapy for locally advanced non-small cell lung cancer
    Lackner, R. P.
    Ganti, A.
    Zhen, W.
    Copur, M. S.
    Vaziri, I. A.
    Bolton, M.
    Hlavaty, T.
    Trujillo, K. P.
    Kessinger, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Trimodality therapy for non-small-cell lung cancer
    Roberts, JR
    [J]. ONCOLOGY-NEW YORK, 1999, 13 (10): : 101 - 106
  • [6] Optimal Timing of Trimodality Therapy in Locally Advanced Non-Small Cell Lung Cancer
    Han, J.
    Hasan, S.
    Choi, I. J.
    Press, R. H.
    Simone, C. B., II
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E150 - E150
  • [7] Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy
    Shimpei Tsudaka
    Hiromasa Yamamoto
    Hiroki Sato
    Kuniaki Katsui
    Ken Suzawa
    Kazuhiko Shien
    Kentaroh Miyoshi
    Shinji Otani
    Mikio Okazaki
    Seiichiro Sugimoto
    Masaomi Yamane
    Katsuyuki Kiura
    Susumu Kanazawa
    Shinichi Toyooka
    [J]. Annals of Surgical Oncology, 2021, 28 : 4880 - 4890
  • [8] Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy
    Tsudaka, Shimpei
    Yamamoto, Hiromasa
    Sato, Hiroki
    Katsui, Kuniaki
    Suzawa, Ken
    Shien, Kazuhiko
    Miyoshi, Kentaroh
    Otani, Shinji
    Okazaki, Mikio
    Sugimoto, Seiichiro
    Yamane, Masaomi
    Kiura, Katsuyuki
    Kanazawa, Susumu
    Toyooka, Shinichi
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (09) : 4880 - 4890
  • [9] Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer
    Soh, Junichi
    Sugimoto, Seiichiro
    Namba, Kei
    Miura, Akihiro
    Shiotani, Toshio
    Yamamoto, Haruchika
    Suzawa, Ken
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Okazaki, Mikio
    Katsui, Kuniaki
    Yamane, Masaomi
    Kiura, Katsuyuki
    Kanazawa, Susumu
    Toyooka, Shinichi
    [J]. ANNALS OF THORACIC SURGERY, 2021, 112 (01): : 279 - 288
  • [10] THE BENEFIT OF ADJUVANT TREATMENT FOR RESECTED LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER
    LAD, T
    RUBINSTEIN, L
    SADEGHI, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) : 9 - 17
12345